A Phase 1 interventional study of SCB0020160 and Placebo in Solid Tumor, Obesity and Idiopathic Pulmonary Fibrosis, sponsored by SCBIO Inc.. Not yet recruiting at 1 site in Australia. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by SCBIO Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.
Among the 188 studies in Obesity with a site in Australia, this one is the 112th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 23 of the 73 other live ones, and was the 173rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Australia, United States, Canada and 2 more countries
Ages 18–99
Verdiva Bio Dev Limited · Sites in Australia
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 34 · Phase 3 59 · Phase 4 8
First in 1995; this study’s year is marked. 41 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 74 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 180 across the 169 interventional studies, 626 across the 19 observational. Of the 97 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 188 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with SCBIO Inc. as lead sponsor.
SCBIO Inc. has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
25 of the studies in Obesity with a site in Australia that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 25 to your calendar (.ics) → With an account.
Among the 188 studies in Obesity with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans.
Healthy adult men aged 18 to 65 years who meet the study eligibility criteria.
Study details
Participants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160.
Participants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse events. The study will also assess how SCB0020160 is processed by the body.
There is no direct health benefit expected from participation. The results may help determine safe dose levels and support future clinical development of SCB0020160.
This study evaluates the safety, tolerability, and pharmacokinetics of SCB0020160 or placebo following single and multiple oral doses in healthy adult male subjects. A total of 74 subjects were planned, including 64 target subjects (8 per dose group) and 10 substitute subjects. The study may be completed without enrolling substitute subjects if all 64 target subjects complete the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Body weight more Than or equals to 45.0 kilograms per square meter at screening, with a (BMI) of more than or equals to18.0-kilogram Meter square and less than or equals to 32.0 Kilograms per meter square
Exclusion Criteria:
[Methods of contraception considered highly effective]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single and multiple oral doses of SCB0020160
Drug: SCB0020160
Matching placebo administered under the same dosing conditions
Drug: Placebo
Single and multiple oral doses of SCB0020160 administered under fasting conditions. A food-effect evaluation following a single oral dose will be conducted in Part A Cohort 4.
Matching placebo administered orally under the same dosing conditions as SCB0020160, including participation in the food-effect evaluation in Part A Cohort 4
Incidence and frequency of adverse events, adverse drug reactions, serious adverse events, and serious adverse drug reactions
Adverse event analysis will be conducted on Treatment Emergent Adverse Events (TEAEs)
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate General Appearance
For General Appearance assessments are: Level of consciousness (alert, oriented) Nutritional status (well/poorly nourished) Build and posture Signs of distress (pain, dyspnea, fatigue) Hygiene and grooming
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate HEENT
For HEENT assessments are: Head: shape, scalp lesions Eyes: pupil size/reactivity (PERRLA), vision, conjunctiva (pallor/icterus) Ears: hearing, discharge Nose: obstruction, discharge Throat: oral mucosa, tonsils, pharynx
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Neck (incl Thyroid & Nodes)
for Neck (incl Thyroid \& Nodes) assessment are: Thyroid size, nodules, tenderness Cervical lymphadenopathy Neck mobility Jugular venous pressure (if relevant
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Cardiovascular
For Cardiovascular assessment are: Heart rate and rhythm Heart sounds (S1, S2, murmurs) Peripheral pulses Edema (peripheral) Blood pressure
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Respiratory
For Respiratory assessment are: Respiratory rate and effort Chest expansion symmetry Breath sounds (normal, wheeze, crackles) Use of accessory muscles
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Gastrointestinal
For Gastrointestinal assessment are: Abdominal inspection (distension, scars) Palpation (tenderness, masses, organomegaly) Percussion (fluid, liver span) Bowel sounds
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Renal
For Renal assessment are: Flank tenderness (costovertebral angle) Bladder distension Urinary symptoms
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Neurological
For Neurological assessment are: Mental status (orientation, cognition) Cranial nerves (if detailed exam required) Motor function (strength, tone) Sensory function Reflexes Coordination and gait
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Musculoskeletal
For Musculoskeletal assessment are: Joint range of motion Swelling or deformities Muscle strength Tenderness
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Physical examination to evaluate Skin
For Skin assessment are: Color (pallor, cyanosis, jaundice) Rashes or lesions Texture and turgor Ulcers or scars
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Vital signs (body temperature (tympanic)
For body temperature (tympanic) the measurement of unit is degree Celsius
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Vital signs (Pulse Rate)
For Pulse Rate the measurement of unit is - beats/min
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Vital signs (Systolic/Diastolic blood pressure)
For Systolic/Diastolic blood pressure the measurement of unit is - mmHg
Time frame: From first dose through Post-Study Visit (up to Day 33)
For 12-lead ECG (electrocardiogram)
The investigator evaluates heart rate (rate and regularity), waveform shape, and overall rhythm; QTcF (msec) is used in the screening criteria will be collectively assessed
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Clinical Laboratory Test which includes Urinalysis
For Urinalysis - Dipstick + microscopy
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Clinical Laboratory Test which includes the Coagulation
For Coagulation - Prothrombin Time (PT) (INR), Activated Partial Thromboplastin Time (aPTT)
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Clinical Laboratory Test which includes the Blood chemistry
For Blood chemistry the test performed will be Calcium, phosphate, glucose, urate, cholesterol, total protein, albumin, total bilirubin, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (γ-GT), Creatine Phosphokinase (CPK), Urea, Lactate Dehydrogenase (LDH), creatinine, Estimated Glomerular Filtration Rate (eGFR) (CKD-EPI), sodium, potassium, chloride, triglyceride, Low-Density Lipoprotein Cholesterol (LDL) \& High-Density Lipoprotein Cholesterol (HDL)
Time frame: From first dose through Post-Study Visit (up to Day 33)
For Clinical Laboratory Test which includes the Hematology
For Hematology the test performed will be white blood cells with differential, Red blood cells, hemoglobin, hematocrit \& platelet
Time frame: From first dose through Post-Study Visit (up to Day 33)
Pharmacokinetic Parameters of SCB0020160 for Cmax
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for Tmax
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for AUClast
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for AUCinf
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for t½
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for CL/F
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for Vz/F
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Pharmacokinetic Parameters of SCB0020160 for MRT
The results of the outcome are collectively measured
Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
Comparison of pharmacokinetic parameters for Cmax of SCB0020160 under fasting and fed conditions following a single oral dose.
The results of the outcome are collectively measured
Time frame: Up to Day 29.
Comparison of pharmacokinetic parameters for Tmax of SCB0020160 under fasting and fed conditions following a single oral dose.
The results of the outcome are collectively measured
Time frame: Up to Day 29.
Comparison of pharmacokinetic parameters for Tlag of SCB0020160 under fasting and fed conditions following a single oral dose.
The results of the outcome are collectively measured
Time frame: Up to Day 29.
Comparison of pharmacokinetic parameters for AUClast of SCB0020160 under fasting and fed conditions following a single oral dose.
The results of the outcome are collectively measured
Time frame: Up to Day 29.
Comparison of pharmacokinetic parameters for AUCinf of SCB0020160 under fasting and fed conditions following a single oral dose.
The results of the outcome are collectively measured
Time frame: Up to Day 29.
Comparison of pharmacokinetic parameters for MRT of SCB0020160 under fasting and fed conditions following a single oral dose.
The results of the outcome are collectively measured
Time frame: Up to Day 29.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 11 months later.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 11 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.